GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 7, 2022, serves as a transaction notification for the month of October 2022. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on October 6, 2022, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (31 1/2 pence each) | £13.3391 | 367 shares |
Note: The total volume of 367 shares is the aggregate of individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine compliance disclosures regarding insider share acquisitions resulting from dividend re-investment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares via dividend re-investment under the Share Reward Plan.
- Participants: Transactions involved 12 individuals, including the CEO (Ms E Walmsley), President of Vaccines (Mr R Connor), and other senior executives.
- Execution Details: All trades occurred on October 6, 2022, at a uniform price of £13.3391 per share.
- Scope: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.